AcelRx is currently seeking commercial and development partners for ARX-04 globally and for Zalviso® in select geographies. Our ideal partners have both broad geographic coverage and a demonstrated track record of success in our target markets.
We welcome the opportunity to talk with potential commercialization partners worldwide about licensing relationships, development collaborations, and strategic alliances that complement and extend our own development and commercial capabilities.
To discuss potential partnering opportunities, please contact:
Meera Desai, Ph.D.
Director, Alliance Management and Corporate Development
ARX-04 is a non-invasive, healthcare provider administered single dose sublingual sufentanil tablet for treatment of patients with moderate-to-severe acute pain in a number of medically supervised settings such as on the battlefield, in the emergency room and in ambulatory care environments. Recently, AcelRx announced that ARX-04 met all endpoints in a Pivotal Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Zalviso is currently approved by the European Commission (EC) for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting. It is marketed by Grünenthal Group, AcelRx's licensee in Europe and Australia.